Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
BioAtla, Inc.
BioAtla is a biotech company developing antibody drugs that are designed to activate only inside tumors, aiming to make cancer treatment more precise and less toxic.
BioAtla is a clinical-stage biotech company that is trying to solve one of cancer medicine's oldest problems: most powerful cancer drugs attack the whole body, not just the tumor. The company engineers antibodies — lab-made proteins that latch onto specific targets — so they stay switched off in healthy tissue and only switch on when they reach the chemical environment of a solid tumor. Its proprietary technology platform, which it calls Conditionally Active Biologics, is the engine behind this idea.
The financial reality is stark and worth saying plainly. BioAtla has no approved product and no product revenue. Like most clinical-stage biotech firms, it burns cash to fund laboratory work and human trials, and it raises money by selling shares rather than by selling medicine. That means investors are betting on future trial results, and the company's survival depends on those results being good enough to attract more capital or a partner. Its lead programs target solid tumors, including a candidate aimed at a protein called CEACAM5, which is found on several cancer types such as lung and colorectal cancer. The pitch to partners and investors is that its antibodies could be safer and more tolerable than conventional ones, because healthy cells are spared. Competitors include larger antibody developers and other biotechs chasing similar "masked" or tumor-selective antibody approaches, and the field has grown crowded.
BioAtla went public on Nasdaq in December 2020, and since then its stock has been volatile, as is typical for small biotech companies waiting on clinical data. The core risk is simple: promising science in a lab does not always become a drug that works in people. Until it reports strong trial results or lands a major partnership, the company is a story about potential, not profits.
Saved answer · last researched 14 Nov 2026